SCHEMBL21986317

SCHEMBL21986317

Cc1cc[c]c(Oc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 2/20 0.38
HTT P42858 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACHE P22303 1/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 2/20 0.34
CYP2A6 P11509 1/20 0.34
MAOB P27338 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28609139 0.83 ALDH1A1 (0.39) TSHRALDH1A1HTTSMN1; SMN2ACHE
SCHEMBL1451634 0.80 LTA4H (0.50) LTA4HTSHRALDH1A1HTTSMN1; SMN2
SCHEMBL1535885 0.80 LTA4H (0.44) LTA4HTSHRSMN1; SMN2TDP1MAOB
SCHEMBL9799454 0.80 LMNA (0.50) ALDH1A1HTTSMN1; SMN2TDP1CYP2A6
SCHEMBL2302914 0.78 LTA4H (0.46) LTA4HTSHRALDH1A1HTTSMN1; SMN2
SCHEMBL1691558 0.77 CYP1A2 (0.44) LTA4HTSHRALDH1A1SMN1; SMN2GAA
SCHEMBL27889013 0.77 LTA4H (0.41) LTA4HTSHRALDH1A1TDP1CYP2A6
SCHEMBL8124330 0.77 LTA4H (0.41) LTA4HTSHRALDH1A1SMN1; SMN2TDP1
SCHEMBL28013409 0.77 LTA4H (0.41) LTA4HTSHRCYP2A6MAOBKMT2A
SCHEMBL8129835 0.76 MCL1 (0.41) LTA4HTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US disclosed
EP-3719022-A1 POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE Janssen Pharmaceutica NV (BE) 2020-10-07 EP disclosed
EP-3386991-B1 POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE JANSSEN PHARMACEUTICA NV (BE) 2020-06-03 EP disclosed
CN-109071563-A Inhibitors of bruton's tyrosine kinase and methods of use thereof 詹森药业有限公司 2018-12-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 LTA4H 2841/4885TSHR 4243/4885ALDH1A1 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.